Please Wait.....
Report
Immunology Market By Product Type (Diagnostic Testing Equipment, Biomarkers, Biopharmaceuticals), By Application (Allergy and Hypersensitivity, Autoimmune Disease, Infectious Disease, HIV and AIDS, Others) By End User (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 231 Pages I Allied Market Research
Immunology Market
The immunology market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.
Immunology is a branch of science involved in studying the immune system of an organism. Immune system is the defense mechanism of a living body which fights against infections, foreign substances, and diseases. Immunology finds applications in diverse disciplines of medicine, including oncology,organ transplantation,rheumatology, bacteriology, virology,parasitology, dermatology, and psychiatry.
The immunology market is driven by rise in prevalence of immunological diseases and surge in awareness among individuals regarding the treatment of such diseases. In addition, governments across the globe have increased their expenditure in the field of science and medicine, thereby augmenting the growth of the immunology market. Boost in the trend of biosimilars and personalized medicine is currently presenting new prospects for the market. Moreover, personalized immunotherapy is projected to become mainstream in the future as a patient's immune profile guides the treatment in this approach, hence elevating the effectiveness of the therapy and medications.
However, drug discovery is a lengthy process in immunology, which often requires 10-15 years of research in the laboratory, hence hampering the market growth. In addition, thestringent compliance requirements and the extended approval procedure of new drugs & treatments is a significant restraint for the market. For instance, the U.S. Food and Drug Administration has implemented a long series of regulations which is necessary to follow before releasing any drug in the market. This series involves preclinical testing, submission of investigational new drug application, three phases of clinical trials, submission of new drug application, and lastly post-market surveillance. Drug manufacturers are obliged to follow the sequence to ensure the efficacy and long-term effects of their medications.
Segment Review
The immunology market is segmented into product type, application, end user, and region. On the basis of product type, the market is divided into diagnostic testing equipment, biomarkers, and biopharmaceuticals. By application, it is classified into allergy & hypersensitivity, autoimmune disease, infectious disease, HIV & AIDS, and others. As per end user, it is categorized into hospitals & clinics, pharmaceutical & biotechnology companies, diagnostic laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the biopharmaceuticals segment is expected to maintain its dominance during the forecast period.
By application, the autoimmune disease segment is projected to garner a high market shareby 2033.
As per end user, the hospitals & clinics segment is anticipated to be the highest shareholder during the forecast period.
Region wise, North America is predicted to maintain its dominance by 2033.
Competition Analysis
The major players operating in theglobal immunology market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company, Gilead Sciences, Inc., and Sanofi. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
- Diagnostic Testing Equipment
- Biomarkers
- Biopharmaceuticals
By Application
- Allergy and Hypersensitivity
- Autoimmune Disease
- Infectious Disease
- HIV and AIDS
- Others
By End User
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Diagnostic Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- AbbVie Inc.
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Amgen Inc.
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Sanofi
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: FLUID SHORTENING MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Normal Type
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Stable Type
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. High Emulsification
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: FLUID SHORTENING MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Baked Food
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Fried Food
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: FLUID SHORTENING MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By Application
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Fluid Shortening Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By Application
6.2.6. Canada Fluid Shortening Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By Application
6.2.7. Mexico Fluid Shortening Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By Application
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By Application
6.3.4. Market Size and Forecast, By Country
6.3.5. France Fluid Shortening Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By Application
6.3.6. Germany Fluid Shortening Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By Application
6.3.7. Italy Fluid Shortening Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By Application
6.3.8. Spain Fluid Shortening Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By Application
6.3.9. UK Fluid Shortening Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By Application
6.3.10. Rest of Europe Fluid Shortening Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By Application
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By Application
6.4.4. Market Size and Forecast, By Country
6.4.5. China Fluid Shortening Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By Application
6.4.6. Japan Fluid Shortening Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By Application
6.4.7. India Fluid Shortening Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By Application
6.4.8. South Korea Fluid Shortening Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By Application
6.4.9. Australia Fluid Shortening Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By Application
6.4.10. Rest of Asia-Pacific Fluid Shortening Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By Application
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By Application
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Fluid Shortening Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By Application
6.5.6. South Africa Fluid Shortening Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By Application
6.5.7. Saudi Arabia Fluid Shortening Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By Application
6.5.8. Argentina Fluid Shortening Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By Application
6.5.9. Rest of LAMEA Fluid Shortening Market
6.5.9.1. Market Size and Forecast, By Type
6.5.9.2. Market Size and Forecast, By Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Archer Daniels Midland Company
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Olenex
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Walter Rau
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. VFI GmbH
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. AAK
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Zeelandia
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Puratos
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Princes Group
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. HAS Group
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Yildiz Holding
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL IMMUNOLOGY MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 2. IMMUNOLOGY MARKET FOR DIAGNOSTIC TESTING EQUIPMENT, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. IMMUNOLOGY MARKET FOR BIOMARKERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. IMMUNOLOGY MARKET FOR BIOPHARMACEUTICALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL IMMUNOLOGY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 6. IMMUNOLOGY MARKET FOR ALLERGY AND HYPERSENSITIVITY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. IMMUNOLOGY MARKET FOR AUTOIMMUNE DISEASE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. IMMUNOLOGY MARKET FOR INFECTIOUS DISEASE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. IMMUNOLOGY MARKET FOR HIV AND AIDS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. IMMUNOLOGY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. GLOBAL IMMUNOLOGY MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 12. IMMUNOLOGY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. IMMUNOLOGY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. IMMUNOLOGY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. IMMUNOLOGY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. IMMUNOLOGY MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 18. NORTH AMERICA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 20. NORTH AMERICA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. U.S. IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 22. U.S. IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 23. U.S. IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 24. CANADA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 25. CANADA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 26. CANADA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 28. MEXICO IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 29. MEXICO IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 31. EUROPE IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 32. EUROPE IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 33. EUROPE IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 34. GERMANY IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 35. GERMANY IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 36. GERMANY IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 37. FRANCE IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 38. FRANCE IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 39. FRANCE IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. UK IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 41. UK IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 42. UK IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. ITALY IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 44. ITALY IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 45. ITALY IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. SPAIN IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 47. SPAIN IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 48. SPAIN IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 49. REST OF EUROPE IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 50. REST OF EUROPE IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 51. REST OF EUROPE IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 53. ASIA-PACIFIC IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 54. ASIA-PACIFIC IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 55. ASIA-PACIFIC IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 56. JAPAN IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 57. JAPAN IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 58. JAPAN IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. CHINA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 60. CHINA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 61. CHINA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 62. INDIA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 63. INDIA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 64. INDIA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 65. AUSTRALIA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 66. AUSTRALIA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 67. AUSTRALIA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 68. SOUTH KOREA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 69. SOUTH KOREA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 70. SOUTH KOREA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 71. REST OF ASIA-PACIFIC IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 72. REST OF ASIA-PACIFIC IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 73. REST OF ASIA-PACIFIC IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA IMMUNOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 75. LAMEA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 76. LAMEA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 77. LAMEA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 78. BRAZIL IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 79. BRAZIL IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 80. BRAZIL IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 81. SAUDI ARABIA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 82. SAUDI ARABIA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 83. SAUDI ARABIA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 84. SOUTH AFRICA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 85. SOUTH AFRICA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 86. SOUTH AFRICA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 87. REST OF LAMEA IMMUNOLOGY, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 88. REST OF LAMEA IMMUNOLOGY, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 89. REST OF LAMEA IMMUNOLOGY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 90. ABBVIE INC.: KEY EXECUTIVES
TABLE 91. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 92. ABBVIE INC.: OPERATING SEGMENTS
TABLE 93. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 94. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 96. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 97. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 98. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 99. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100. PFIZER INC.: KEY EXECUTIVES
TABLE 101. PFIZER INC.: COMPANY SNAPSHOT
TABLE 102. PFIZER INC.: OPERATING SEGMENTS
TABLE 103. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 104. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. NOVARTIS AG: KEY EXECUTIVES
TABLE 106. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 107. NOVARTIS AG: OPERATING SEGMENTS
TABLE 108. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 109. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 111. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 112. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 113. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 114. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. AMGEN INC.: KEY EXECUTIVES
TABLE 121. AMGEN INC.: COMPANY SNAPSHOT
TABLE 122. AMGEN INC.: OPERATING SEGMENTS
TABLE 123. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 124. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 126. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 127. ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 128. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 129. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 131. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 132. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 133. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 134. GILEAD SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 135. SANOFI: KEY EXECUTIVES
TABLE 136. SANOFI: COMPANY SNAPSHOT
TABLE 137. SANOFI: OPERATING SEGMENTS
TABLE 138. SANOFI: PRODUCT PORTFOLIO
TABLE 139. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL IMMUNOLOGY MARKET SEGMENTATION
FIGURE 2. GLOBAL IMMUNOLOGY MARKET
FIGURE 3. SEGMENTATION IMMUNOLOGY MARKET
FIGURE 4. TOP INVESTMENT POCKET IN IMMUNOLOGY MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMMUNOLOGY MARKET
FIGURE 11. GLOBAL IMMUNOLOGY MARKET SEGMENTATION, BY PRODUCT TYPE
FIGURE 12. IMMUNOLOGY MARKET FOR DIAGNOSTIC TESTING EQUIPMENT, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. IMMUNOLOGY MARKET FOR BIOMARKERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. IMMUNOLOGY MARKET FOR BIOPHARMACEUTICALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. GLOBAL IMMUNOLOGY MARKET SEGMENTATION, BY APPLICATION
FIGURE 16. IMMUNOLOGY MARKET FOR ALLERGY AND HYPERSENSITIVITY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. IMMUNOLOGY MARKET FOR AUTOIMMUNE DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. IMMUNOLOGY MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. IMMUNOLOGY MARKET FOR HIV AND AIDS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. IMMUNOLOGY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. GLOBAL IMMUNOLOGY MARKET SEGMENTATION, BY END USER
FIGURE 22. IMMUNOLOGY MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. IMMUNOLOGY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. IMMUNOLOGY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. IMMUNOLOGY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 30. COMPETITIVE DASHBOARD
FIGURE 31. COMPETITIVE HEATMAP: IMMUNOLOGY MARKET
FIGURE 32. TOP PLAYER POSITIONING, 2023
FIGURE 33. ABBVIE INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. ABBVIE INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. AMGEN INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. AMGEN INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. ELI LILLY AND COMPANY: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. GILEAD SCIENCES, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. GILEAD SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. GILEAD SCIENCES, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 61. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security